Coastal Infusion Administers Amvuttra

Amvuttra® (vutrisiran) is designed to treat hereditary transthyretin (hATTR) amyloidosis with polyneuropathy, previously referred to as familial amyloid polyneuropathy. This rare genetic disorder is caused by the abnormal buildup of transthyretin proteins in diverse tissues and impacts the peripheral nerves.

Amvuttra is classified as a gene-silencer, aiming to inhibit production of the transthyretin (TTR) protein in the liver, thereby reducing the levels of TTR in the body. The active ingredient, vutrisiran, prevents amyloid build-up and organ damage.

What It Treats

• Hereditary transthyretin (hATTR) amyloidosis with polyneuropathy
• Familial Amyloid Polyneuropathy

Prescribed By

Amvuttra is most often prescribed by Neurologists and Geneticists.

How it's Administered

Amvuttra is administered by subcutaneous injection. Amvuttra injections only take a few minutes.

Frequency

Amvuttra is administered once every 3 months.

Related Drugs

Onpattro

Additional Resources

The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies